In a thematic debut, Jörn Schattenberg and Roger Green host interviews with three listeners from the Surfing NASH community to discuss four prominent questions around:
- the “straightjacket” of biopsy
- how we think about “tests” when not classed as “NITs” as compared to biopsy
- how do we all become better centered on patient needs
- the idea of combination therapy
In this final installment, Clinical Development lead at Sonic Incytes, Caitlin Schneider, joins Roger to discuss NASH-TAG 2023 and the future of Fatty Liver.
In this final installment, Clinical Development lead at Sonic Incytes, Caitlin Schneider, joins Roger to discuss NASH-TAG 2023 and the future of Fatty Liver. After discovering that Caitlin and Roger share one unusual detail in their pasts, they dive into a discussion of the conference. Sonic Incytes developed and markets Velacur, an in-office imaging solution. Not surprisingly, much of Caitlin’s focus revolves around imaging diagnostics and their benefits against biopsy and larger imaging technologies like MRE and MRI-PDFF.
Each guest in these fully-featured interviews shares on-ground experiences which collectively cast invaluable light on how the information featured in Surfing the NASH Tsunami is digested and applied in everyday life. As the podcast enters its fourth season, and embarks on affiliated journeys like the Rising Tide series, we hope to grow our community engagement. If you enjoy our content, we kindly ask that you submit a review wherever you download our episodes. We also encourage our audience to write us questions and look forward to integrating your on-ground experiences and perspectives in the weekly discourse.
Most important of all, we whole-heartedly thank you for your continued support as we set out to put a major dent in Fatty Liver disease in 2023 and beyond.
